Evidence-Based Complementary and Alternative Medicine / 2013 / Article / Tab 1

Review Article

A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency

Table 1

Characteristics of RCT on CVI and microangiopathy included in this study.

StudyParticipantsIntervention (dose) Duration of studyControl

Allegra et al., 1981 [38]Patients with venous insufficiency of the lower limbsTTFCA (60 mg/day)8030 daysplacebo
Marastoni et al., 1982 [39]Patients with CVI Centella asiatica extract (tid)*174 weekstribenoside
Pointel et al., 1987 [40]Patients with venous insufficiency of the lower limbsTTFCA (60 mg; 120 mg)948 weeksplacebo
Cesarone et al., 1994 [41]Patients with chronic venous hypertensive microangiopathyTTFCA (30 mg bid; 60 mg bid)9060 daysplacebo
Cesarone et al., 2001 [42]Patients with severe venous hypertension, ankle swelling, and lipodermatosclerosisTTFCA (60 mg bid)408 weeksplacebo
Cesarone et al., 2001 [43]Patients with venous hypertension with ankle and foot swelling, oedema, and lipodermatosclerosis, with intact skinTTFCA (60 mg bid)406 weeksplacebo
De Sanctis et al., 2001 [44]Patients with venous hypertension (ambulatory venous pressure > 42 mm Hg)TTFCA (30 mg tid; 60 mg tid)624 weeksplacebo
Incandela et al., 2001 [45]Patients with venous hypertensive microangiopathyTTFCA (60 mg daily; 120 mg daily)998 weeksplacebo

TTFCA: total triterpenic fraction of Centella asiatica.
*Extract dosage not reported.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.